ArticleAging2021
Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database.
Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 73 citations in OpenAlex.
- The NKp44-1 Isoform Is an Activating Receptor for PDGF-DD Expressed on Natural Killer Cells.Cancers · 2026Article
- Characterization of Immune Infiltrating Cells in Bladder Urothelial Carcinoma and Its Clinical Significance.Cancer medicine · 2026Article
- Clinical Significance of RBM15 in Gastric Cancer: A Multi-Database Validation.Current medicinal chemistry · 2026Article
- An interpretable CT-based deep learning model for predicting overall survival in patients with bladder cancer: a multicenter study.NPJ precision oncology · 2025Article
- Deciphering the oncogenic role of Rac family small GTPase 3 in hepatocellular carcinoma through multiomics integration.World journal of hepatology · 2025Article
- Disulfidptosis related immune genes drive prognostic model development and tumor microenvironment characterization in bladder urothelial carcinoma.Scientific reports · 2025Article
- WD40 Protein NLE1 as a Novel Diagnostic Biomarker Promoting Hepatocellular Carcinoma Proliferation.Clinical Medicine Insights. Oncology · 2025Article
- EDNRA regulates the tumour immune environment and predicts the efficacy and prognosis of cancer immunotherapy.Journal of cellular and molecular medicine · 2024Article
- Exploring the impact of PDGFD in osteosarcoma metastasis through single-cell sequencing analysis.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Prognostic value and molecular mechanisms of OAS1 in lung adenocarcinoma.BMC pulmonary medicine · 2024Article
- Evaluation of circulating plasma proteins in prostate cancer using mendelian randomization.Discover oncology · 2024Article
- Unveiling the role of RAC3 in the growth and invasion of cisplatin-resistant bladder cancer cells.Journal of cellular and molecular medicine · 2024Article
- Early diagnosis and prognostic potential of RAC3 in bladder tumor.International urology and nephrology · 2024Article
- Development of a prognostic signature for immune-associated genes in bladder cancer and exploring potential drug findings.International urology and nephrology · 2024Article
- Deciphering the significance of anoikis in bladder cancer and systematic analysis of S100A7 as a potential therapeutic target.European journal of medical research · 2024Article
- A risk model based on lncRNA-miRNA-mRNA gene signature for predicting prognosis of patients with bladder cancer.Cancer biomarkers : section A of Disease markers · 2024Article
- Comprehensive Analysis of the Significance of Breast Cancer Gene 1 (BRCA-1) in Bladder Cancer.Cancer management and research · 2024Article
- Prediction of immune infiltration and prognosis for patients with gastric cancer based on the immune-related genes signature.Heliyon · 2023Article
- A novel immune score model predicting the prognosis and immunotherapy response of breast cancer.Scientific reports · 2023Article
- Expression pattern, tumor immune landscape, and prognostic value of N7‑methylguanosine regulators in bladder urothelial carcinoma.Oncology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMuscle-invasive bladder cancer (MIBC) with high tumor stages accounts for most bladder cancer patient mortality. Platinum-based chemotherapy provides insufficient survival benefits; however, immunotherapy is a promising option for MIBC.
resultsThere were 31 differentially expressed IRGs that significantly correlated with the clinical outcomes of MIBC patients. A prognostic signature based on 12 IRGs (MMP9, RBP7, ADIPOQ, AHNAK, OAS1, RAC3, SLIT2, EDNRA, IL34, PDGFD, PPY, IL17RD) performed moderately in prognostic predictions with area under the curve (AUC) equal to 0.76. The high-risk patient group presented worse survival outcomes (hazard ratio 1.197, 95% confidence interval 1.103-1.299,
conclusionThis novel prognostic signature can effectively divide MIBC patients into different risk groups, allowing for intensive treatment of high-risk individuals who have worse predicted survival outcomes.
methodsBioinformatics analyses were conducted using the Cancer Genome Atlas (TCGA) database. Differentially expressed genes and survival-associated immune-related genes (IRGs) were analyzed through a computational algorithm and Cox regression. The potential mechanisms of IRG expression were explored with transcription factors, and a prognosis classification based on IRG expression was developed to stratify patients into distinct risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.